New reports detail the spread of SARS-CoV-2 variant BA.3.2, Long COVID disability burden, sarbecovirus cross-immunity, and how stacked outpatient risk factors shape severe COVID-19 outcomes.
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
A multisite surveillance study published in Pediatrics assessed trends and determinants of influenza antiviral use in hospitalized children across the United States before and during the late COVID-19...
This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.
A large multinational cohort study evaluated whether COVID-19 vaccination during pregnancy reduces the risk of preeclampsia, a major hypertensive complication associated with SARS-CoV-2 infection.
The FDA has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for adults and pediatric patients aged 12 years and older with previously untreated stage III or IV...
